AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Q2 2025 Management View CEO Christopher S. Boerner highlighted, "Our growth portfolio delivered another strong quarter with sales increasing 17% year-over-year, primarily driven by demand across all ...

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Speaking during the Fierce JPM Week virtual conference, Bristol's CMO, Samit Hirawat, said the company's deucravacitinib is a novel TYK2 inhibitor "with a very specific downstream effect of ...

Bristol-Myers Squibb Co is confident it will receive U.S. approvals for all three experimental drugs tied to a potentially higher payout for Celgene shareholders under terms of its acquisition of ...

One such company is Bristol Myers Squibb Co. (Symbol: BMY), which saw buying by EVP,Chief Med.Offr.,Drug Dev. Samit Hirawat. Back on April 25, Hirawat invested $202,215.00 into 4,250 shares of BMY ...